Clinical Trial Update: A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and Pharmacodynamics [Phase 1]

View source ↗

Summary

Phase 1, single-dose study of JZP-386 to evaluate safety, pharmacokinetics and pharmacodynamics has completed, sponsored by Concert Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Excessive Daytime Sleepiness
• Narcolepsy

Drugs mentioned

• JZP-386

Snippet

Sponsor: Concert Pharmaceuticals | Conditions: Narcolepsy, Excessive Daytime Sleepiness | Phase 1 | Status: COMPLETED